314 related articles for article (PubMed ID: 12067438)
41. Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS.
Das MM; Svendsen CN
Neurobiol Aging; 2015 Feb; 36(2):1130-9. PubMed ID: 25443290
[TBL] [Abstract][Full Text] [Related]
42. The cellular mRNA expression of GABA and glutamate receptors in spinal motor neurons of SOD1 mice.
Petri S; Schmalbach S; Grosskreutz J; Krampfl K; Grothe C; Dengler R; Van Den Bosch L; Robberecht W; Bufler J
J Neurol Sci; 2005 Nov; 238(1-2):25-30. PubMed ID: 16087196
[TBL] [Abstract][Full Text] [Related]
43. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis.
Bordet T; Buisson B; Michaud M; Drouot C; Galéa P; Delaage P; Akentieva NP; Evers AS; Covey DF; Ostuni MA; Lacapère JJ; Massaad C; Schumacher M; Steidl EM; Maux D; Delaage M; Henderson CE; Pruss RM
J Pharmacol Exp Ther; 2007 Aug; 322(2):709-20. PubMed ID: 17496168
[TBL] [Abstract][Full Text] [Related]
44. Adult olfactory bulb neural precursor cell grafts provide temporary protection from motor neuron degeneration, improve motor function, and extend survival in amyotrophic lateral sclerosis mice.
Martin LJ; Liu Z
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1002-18. PubMed ID: 17984682
[TBL] [Abstract][Full Text] [Related]
45. Adeno-associated virus-mediated delivery of glial cell line-derived neurotrophic factor protects motor neuron-like cells from apoptosis.
Keir SD; Xiao X; Li J; Kennedy PG
J Neurovirol; 2001 Oct; 7(5):437-46. PubMed ID: 11582516
[TBL] [Abstract][Full Text] [Related]
46. Transplanted modified muscle progenitor cells expressing a mixture of neurotrophic factors delay disease onset and enhance survival in the SOD1 mouse model of ALS.
Dadon-Nachum M; Ben-Yaacov K; Ben-Zur T; Barhum Y; Yaffe D; Perlson E; Offen D
J Mol Neurosci; 2015 Mar; 55(3):788-97. PubMed ID: 25330859
[TBL] [Abstract][Full Text] [Related]
47. Has gene therapy for ALS arrived?
Miller TM; Cleveland DW
Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
[No Abstract] [Full Text] [Related]
48. A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in a symptomatic mouse ALS model.
Ciriza J; Moreno-Igoa M; Calvo AC; Yague G; Palacio J; Miana-Mena FJ; Muñoz MJ; Zaragoza P; Brûlet P; Osta R
Restor Neurol Neurosci; 2008; 26(6):459-65. PubMed ID: 19096133
[TBL] [Abstract][Full Text] [Related]
49. Non-viral gene delivery of the GDNF, either alone or fused to the C-fragment of tetanus toxin protein, prolongs survival in a mouse ALS model.
Moreno-Igoa M; Calvo AC; Ciriza J; Muñoz MJ; Zaragoza P; Osta R
Restor Neurol Neurosci; 2012; 30(1):69-80. PubMed ID: 22124037
[TBL] [Abstract][Full Text] [Related]
50. Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.
Tanase K; Teng Q; Krishnaney AA; Liu JK; Garrity-Moses ME; Boulis NM
J Neurosurg Spine; 2004 Jul; 1(1):128-36. PubMed ID: 15291033
[TBL] [Abstract][Full Text] [Related]
51. Ex Vivo Gene Therapy Using Human Mesenchymal Stem Cells to Deliver Growth Factors in the Skeletal Muscle of a Familial ALS Rat Model.
Suzuki M; Svendsen CN
Methods Mol Biol; 2016; 1382():325-36. PubMed ID: 26611598
[TBL] [Abstract][Full Text] [Related]
52. Unchanged Neurotrophic Factors and Their Receptors Correlate With Sparing in Extraocular Muscles in Amyotrophic Lateral Sclerosis.
Harandi VM; Gaied AR; Brännström T; Pedrosa Domellöf F; Liu JX
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6831-6842. PubMed ID: 28002846
[TBL] [Abstract][Full Text] [Related]
53. Differential expression of molecular motors in the motor cortex of sporadic ALS.
Pantelidou M; Zographos SE; Lederer CW; Kyriakides T; Pfaffl MW; Santama N
Neurobiol Dis; 2007 Jun; 26(3):577-89. PubMed ID: 17418584
[TBL] [Abstract][Full Text] [Related]
54. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model.
Krakora D; Mulcrone P; Meyer M; Lewis C; Bernau K; Gowing G; Zimprich C; Aebischer P; Svendsen CN; Suzuki M
Mol Ther; 2013 Aug; 21(8):1602-10. PubMed ID: 23712039
[TBL] [Abstract][Full Text] [Related]
55. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H; Yang B; Qiu L; Yang C; Kramer J; Su Q; Guo Y; Brown RH; Gao G; Xu Z
Hum Mol Genet; 2014 Feb; 23(3):668-81. PubMed ID: 24108104
[TBL] [Abstract][Full Text] [Related]
56. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.
Towne C; Setola V; Schneider BL; Aebischer P
Mol Ther; 2011 Feb; 19(2):274-83. PubMed ID: 21102563
[TBL] [Abstract][Full Text] [Related]
57. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport.
Lu YY; Wang LJ; Muramatsu S; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Matsushita T; Hanazono Y; Kume A; Nagatsu T; Ozawa K; Nakano I
Neurosci Res; 2003 Jan; 45(1):33-40. PubMed ID: 12507722
[TBL] [Abstract][Full Text] [Related]
58. Prevention of motoneuron death by adenovirus-mediated neurotrophic factors.
Giménez y Ribotta M; Revah F; Pradier L; Loquet I; Mallet J; Privat A
J Neurosci Res; 1997 May; 48(3):281-5. PubMed ID: 9160251
[TBL] [Abstract][Full Text] [Related]
59. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
Towne C; Aebischer P
Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
[TBL] [Abstract][Full Text] [Related]
60. Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats.
Kliem MA; Heeke BL; Franz CK; Radovitskiy I; Raore B; Barrow E; Snyder BR; Federici T; Kaye Spratt S; Boulis NM
Amyotroph Lateral Scler; 2011 Sep; 12(5):331-9. PubMed ID: 21864053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
